Zacks Research Has Negative Forecast for Zoetis Q1 Earnings

Zoetis Inc. (NYSE:ZTS) – Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for Zoetis in a research report issued on Thursday, March 6th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $1.39 per share for the quarter, down from their previous forecast of $1.45. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis’ Q2 2025 earnings at $1.60 EPS, Q3 2025 earnings at $1.62 EPS, Q4 2025 earnings at $1.46 EPS, FY2025 earnings at $6.07 EPS, Q1 2026 earnings at $1.54 EPS, Q2 2026 earnings at $1.66 EPS, Q3 2026 earnings at $1.69 EPS and FY2027 earnings at $6.97 EPS.

Several other research analysts also recently commented on the company. Barclays lifted their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Stifel Nicolaus reduced their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, Leerink Partners assumed coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Two analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $215.90.

Zoetis Stock Up 0.2 %

ZTS opened at $167.26 on Friday. The company has a market cap of $74.90 billion, a P/E ratio of 30.58, a P/E/G ratio of 2.78 and a beta of 0.94. The business’s 50-day moving average price is $166.61 and its 200-day moving average price is $176.92. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis has a 12 month low of $144.80 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Institutional Trading of Zoetis

Hedge funds have recently made changes to their positions in the stock. Callahan Advisors LLC boosted its position in shares of Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after purchasing an additional 6,221 shares in the last quarter. Pensionfund Sabic boosted its position in shares of Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after purchasing an additional 4,000 shares in the last quarter. CIBC Asset Management Inc boosted its position in shares of Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after purchasing an additional 46,050 shares in the last quarter. PFW Advisors LLC bought a new stake in shares of Zoetis in the 4th quarter worth approximately $1,764,000. Finally, Alberta Investment Management Corp boosted its position in shares of Zoetis by 2,050.0% in the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after purchasing an additional 28,700 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.